Incoming Moelis CEO on M&A, Private Capital and Hiring
Incoming Moelis & Co. CEO Navid Mahmoodzadegan discusses his new role as CEO, the outlook for M&A activity and the sate of private capital with Sonali Basak on Bloomberg Television. (Source: Bloomberg)
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
19 minutes ago
- Yahoo
Reddit (RDDT) Unveils AI-Powered Ad Features — Is RDDT the Next AI Stock to Watch?
Reddit, Inc. (NYSE:RDDT) is one of the . On June 16, the company announced the launch of two new AI-powered advertising features at the Cannes Lions 2025, designed to help brands drive greater engagement by tapping user conversations on the platform. Powered by Reddit Community Intelligence, its first AI-driven social listening tool, 'Reddit Insights', aims to provide marketers with real-time insights for planning campaigns. This is done by identifying trends on the platform and testing campaign ideas. The company will also be offering a 'Conversation Summary Add-ons' feature. This feature will enable brands to integrate positive user comments directly beneath their advertisements to demonstrate what users think about the ad's subject. Together, the new AI-driven marketing capabilities will allow marketers to better leverage user discussions from the platform for improving their advertising effectiveness. 'These new products are features I've wanted to build since my first day at Reddit. In a world increasingly flattened by AI, the value of human content on our platform only grows. With Reddit Community Intelligence™, we're not just surfacing insights and conversations; we're offering deep context, perspective, and the voice of real people at scale.' -Jen Wong, Chief Operating Officer at Reddit. Reddit, Inc. (NYSE:RDDT) is a social media platform that leverages AI to strengthen search functionality and improve user engagement. While we acknowledge the potential of RDDT as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and Disclosure: None.
Yahoo
19 minutes ago
- Yahoo
Jefferies Raises Twilio (TWLO)'s Price Target — But Cautions on Most Optimistic Forecasts
Twilio Inc. (NYSE:TWLO) is one of the . On June 15, Jefferies analyst Samad Samana raised the firm's price target on the stock to $132 from $122 and kept a 'Hold' rating on the shares. The analyst told investors in a research note how investors have been debating whether growth can accelerate against the second-half of the year comparisons. They are wondering whether gross margins will rebound or if healthy EBIT beats are sustainable. A financial analyst studying the fundamentals of a co-managed portfolio of mid-cap companies. According to the firm, growth acceleration for Twilio is achievable and makes for a 'good tactical setup' in the shares. However, it doesn't think that most bullish assumptions are achievable. Twilio Inc. (NYSE:TWLO) is a leading cloud communications platform-as-a-service (CPaaS) company. While we acknowledge the potential of TWLO as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
19 minutes ago
- Yahoo
Enzo Biochem: Fiscal Q3 Earnings Snapshot
FARMINGDALE, N.Y. (AP) — FARMINGDALE, N.Y. (AP) — Enzo Biochem Inc. (ENZB) on Monday reported a loss of $2.8 million in its fiscal third quarter. On a per-share basis, the Farmingdale, New York-based company said it had a loss of 5 cents. Losses, adjusted to account for discontinued operations and non-recurring costs, were 4 cents per share. The life sciences and biotechnology company posted revenue of $6.4 million in the period. _____ This story was generated by Automated Insights ( using data from Zacks Investment Research. Access a Zacks stock report on ENZB at Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
